SCHEMBL7474377

SCHEMBL7474377

COc1nc2ccccc2nc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 4/20 0.56
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
HRH4 Q9H3N8 1/20 0.53
MAPT P10636 2/20 0.53
ALDH1A1 P00352 4/20 0.52
KDM4E B2RXH2 3/20 0.52
POLB P06746 2/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
HDAC6 Q9UBN7 1/20 0.52
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
TSHR P16473 1/20 0.48
CYP2C9 P11712 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22929108 0.89 NQO2 (0.47) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL804981 0.85 TSHR (0.61) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL4684319 0.84 KDM4E (0.58) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL14624137 0.84 NQO2 (0.52) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL12498159 0.84 NQO2 (0.47) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL6873559 0.84 NQO2 (0.47) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL5574299 0.84 NQO2 (0.47) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL2178510 0.84 TDP1 (0.58) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL8024194 0.80 NQO2 (0.44) NQO2MEN1KMT2AHRH4MAPT
SCHEMBL7735370 0.80 KDM4E (0.65) MEN1KMT2AALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1261353-A Inhibition of platelet-derived growth factor and/or p56lckQuinoline and quinoxaline compounds of tyrosine kinases RHONE POULENC RORER PHARMA (US) 2000-07-26 CN claimed
CN-107033076-B Polymerizable liquid crystal compound, composition, liquid crystal polymer films thereof, method for producing same, and use thereof 捷恩智株式会社 2021-11-02 CN disclosed
US-10581022-B2 Polymerizable liquid crystal compound, composition, liquid crystal polymerization film-kind thereof and use thereof JNC CORPORATION (JP) 2020-03-03 US disclosed
CN-108020989-A Photosensitive resin composition, color filter, method for manufacturing the same, and application thereof 奇美实业股份有限公司 2018-05-11 CN disclosed
CN-107561859-A Black photosensitive resin composition and application thereof 奇美实业股份有限公司 2018-01-09 CN disclosed
CN-107463067-A Black photosensitive resin composition and application thereof 奇美实业股份有限公司 2017-12-12 CN disclosed
CN-107132730-A Photosensitive resin composition and application thereof 奇美实业股份有限公司 2017-09-05 CN disclosed
CN-107132729-A Photosensitive resin composition and application thereof 奇美实业股份有限公司 2017-09-05 CN disclosed
CN-107015435-A Photosensitive resin composition, color filter and manufacturing method and application thereof 奇美实业股份有限公司 2017-08-04 CN disclosed
CN-106959581-A Photosensitive resin composition and application thereof 奇美实业股份有限公司 2017-07-18 CN disclosed
US-5852016-A Quinoxaline derivatives useful in therapy PFIZER INC. (US) 1998-12-22 US disclosed
CN-1194649-A Quinoxaline-and quinoxalinylalkane-phosphonic acids NOVARTIS AG (CH) 1998-09-30 CN disclosed
CN-1193968-A 2,3-dioxo-1,2,3,4-tetrahydro-quinoyxalinyl derivatives NOVARTIS AG (CH) 1998-09-23 CN disclosed
US-5783572-A TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC. (US) 1998-07-21 US disclosed
WO-1997032873-A1 QUINOXALINEDIONES PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) 1997-09-12 WO disclosed
CN-1158610-A Quinoxaline derivatives useful in therapy PFIZER LTD (IE) 1997-09-03 CN disclosed
EP-0783495-A1 QUINOXALINE DERIVATIVES USEFUL IN THERAPY Pfizer Limited (GB) 1997-07-16 EP disclosed
EP-0781279-A1 QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS Pfizer Limited (GB) 1997-07-02 EP disclosed
WO-1996009295-A1 QUINOXALINE DERIVATIVES USEFUL IN THERAPY PFIZER LIMITED (GB) 1996-03-28 WO disclosed
WO-1996008485-A1 QUINOXALINEDIONE NMDA RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 1996-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10581022-B2 Polymerizable liquid crystal compound, composition, liquid crystal polymerization film-kind thereof and use thereof RCC1, CHRM1, PFN1 NQO2 939/4885MEN1 212/4885KMT2A 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.